Cardiomyopathy, Hypertrophic

"Cardiomyopathy, Hypertrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Descriptor ID	D002312
MeSH Number(s)	C14.280.238.100 C14.280.484.150.070.160
Concept/Terms	Cardiomyopathy, Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathies, Hypertrophic Hypertrophic Cardiomyopathies Hypertrophic Cardiomyopathy Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathies, Hypertrophic Obstructive Hypertrophic Obstructive Cardiomyopathies Hypertrophic Obstructive Cardiomyopathy Obstructive Cardiomyopathies, Hypertrophic Obstructive Cardiomyopathy, Hypertrophic

Below are MeSH descriptors whose meaning is more general than "Cardiomyopathy, Hypertrophic".

Diseases [C]
Cardiovascular Diseases [C14]
Heart Diseases [C14.280]
Cardiomyopathies [C14.280.238]
Cardiomyopathy, Hypertrophic [C14.280.238.100]
Heart Valve Diseases [C14.280.484]
Aortic Valve Stenosis [C14.280.484.150]
Aortic Stenosis, Subvalvular [C14.280.484.150.070]
Cardiomyopathy, Hypertrophic [C14.280.484.150.070.160]

Below are MeSH descriptors whose meaning is related to "Cardiomyopathy, Hypertrophic".

Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathy, Hypertrophic".

Cardiomyopathy, Hypertrophic
Cardiomyopathy, Hypertrophic, Familial

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiomyopathy, Hypertrophic" by people in this website by year, and whether "Cardiomyopathy, Hypertrophic" was a major or minor topic of these publications.

Bar chart showing 430 publications over 25 distinct years, with a maximum of 31 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	1	2
2002	6	1	7
2003	8	0	8
2004	11	0	11
2005	13	1	14
2006	8	0	8
2007	16	2	18
2008	10	2	12
2009	25	1	26
2010	20	0	20
2011	19	0	19
2012	14	0	14
2013	11	0	11
2014	20	0	20
2015	25	2	27
2016	20	1	21
2017	20	0	20
2018	15	0	15
2019	22	0	22
2020	26	1	27
2021	18	0	18
2022	31	0	31
2023	17	0	17
2024	29	1	30
2025	12	0	12

Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.

Saad AM, Abozenah M, Salerno C, Goldsweig AM. Sex differences in in-hospital outcomes in hypertrophic cardiomyopathy: A nationwide analysis. Curr Probl Cardiol. 2025 Nov; 50(11):103172.

View in: PubMed
Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11; 393(10):949-960.

View in: PubMed
Landsteiner I, Masri A, Saberi S, Maron MS, McGinnis SL, Griskowitz C, Newlands CE, Barriales-Villa R, Owens AT, Lewis GD. Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta-Analysis. J Am Heart Assoc. 2025 Sep 02; 14(17):e039551.

View in: PubMed
Narvaez-Guerra O, Botros M, Offord E, Aurigemma G. Phenotypic overlap in apical hypertrophic cardiomyopathy: one size does not fit all. BMJ Case Rep. 2025 Aug 27; 18(8).

View in: PubMed
Sangha V, Dhingra LS, Aminorroaya A, Croon PM, Sikand NV, Sen S, Martinez MW, Maron MS, Krumholz HM, Asselbergs FW, Oikonomou EK, Khera R. Identification of hypertrophic cardiomyopathy on electrocardiographic images with deep learning. Nat Cardiovasc Res. 2025 Aug; 4(8):991-1000.

View in: PubMed
Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats CJ, Fifer MA, Sherrid MV, Solomon SD, Watkins H, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Maron MS, Masri A. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025 Aug; 13(8):102496.

View in: PubMed
Pronovost H, Kassamali AA, Ehmsen J, Rivers B, Gasperetti A, Wu KC, Rowin E, Madrazo JA, Carrick RT. External validation of atrial fibrillation risk prediction tools in a racially diverse cohort of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2025 Oct; 22(10):e841-e848.

View in: PubMed
Sayed A, Maron BJ, Rowin EJ, Maron MS. Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID-19 Pandemic. J Am Heart Assoc. 2025 Apr; 14(7):e037047.

View in: PubMed
Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, Garcia-Pavia P, Olivotto I, Owens AT, Coats CJ, Abraham TP, Solomon SD, Maron MS, Masri A. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2025 Mar 18; 14(6):e038758.

View in: PubMed
Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 May 01; 426:133082.

View in: PubMed

People

Explore

Similar Concepts

Top Journals